華平股份(300074.SZ):230.6萬股限制性股票完成回購註銷
格隆匯 9 月 22日丨華平股份(300074.SZ)公佈,部分限制性股票回購註銷完成,本次回購註銷涉及限制性股票激勵計劃人數合計為140人,共計230.6萬股,約佔回購前公司股本總額的0.43%。其中回購註銷129名激勵對象因未達到激勵計劃規定的解除限售條件所獲授的2017年限制性股票尚未解除限售的第三個解除限售期對應的限制性股票197.4萬股;回購註銷11名激勵對象因個人原因離職不再符合激勵條件所獲授的2017年限制性股票第三個解除限售期對應的限制性股票33.2萬股。
2、經中國證券登記結算有限責任公司深圳分公司審核確認,公司本次部分限制性股票回購註銷事宜已於2020年9月18日辦理完成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.